RA Capital Management’s Coherus Oncology CHRS Stock Holding History

RA Capital Management’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-1,272,048	Closed	-$27M	–	35
2016 Q1	$27M	Hold	1,272,048	–	–	3.45%	9
2015 Q4	$29.2M	Sell	1,272,048 -32,972	-3%	-$849K	2.89%	11
2015 Q3	$26.2M	Sell	1,305,020 -75,300	-5%	-$2.29M	3.76%	7
2015 Q2	$39.9M	Sell	1,380,320 -175,035	-11%	-$4.42M	4.01%	7
2015 Q1	$47.6M	Hold	1,555,355	–	–	4.72%	9
2014 Q4	$25.4M	Buy	+1,555,355	New	+$21.9M	2.73%	11

Other funds holding CHRS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

VHCP Management New York $93M AUM 10.04% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

RA Capital Management's CHRS Position: Q2 2016 in Review

RA Capital Management sold out of Coherus Oncology (CHRS) in Q2 2016, closing a stake of 1,272,048 shares — an estimated $27M sold.

RA Capital Management first reported a position in CHRS in Q4 2014 and held it in 6 quarters. The position peaked at $47.6M in Q1 2015. 86 funds tracked by Wall St. Rank hold CHRS as of Q2 2016.

RA Capital Management reported no remaining Coherus Oncology position as of Q2 2016 after selling out during the quarter.
RA Capital Management sold 1,272,048 Coherus Oncology shares in Q2 2016, an estimated $27M.
RA Capital Management first reported a position in Coherus Oncology in Q4 2014 and held it in 6 quarters.
RA Capital Management's Coherus Oncology position peaked at $47.6M in Q1 2015.
86 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2016.

Based on RA Capital Management's 13F filing for Q2 2016, filed 15 Aug 2016.